Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study

Clinical Therapeutics

Volumn 29, Issue 5, 2007, Pages 844-855

  Lewin, Andrew ^a   Lipetz, Robert ^b   Wu, Jacqueline ^c   Schwartz, Sherwyn ^d  

^a NATIONAL RESEARCH INSTITUTE   (United States)

^b Encompass Clinical Research   (United States)

^c Pharmacokinetics Depomed Inc   (United States)

^d Diabetes and Glandular Disease Clinic   (United States)

Author keywords

combination treatment; extended release; glycemic control; metformin; monotherapy; sulfonylurea

Indexed keywords

FRUCTOSAMINE; GLIBENCLAMIDE PLUS METFORMIN; GLYCOSYLATED HEMOGLOBIN; METFORMIN; PLACEBO; SULFONYLUREA;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; TREMOR; VOMITING;

ADOLESCENT; ADULT; AGED; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED;

EID: 34547650859     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.05.013     Document Type: Article

References (21)

1. [published correction appears in Diabetes Care. 2006;49:2816-2818]. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 29 (2006) 1963-1972
2. DeFronzo R.A., Goodman A.M., and Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 333 (1995) 541-549
3. Hermann L.S., Schersten B., Bitzen P.O., et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 17 (1994) 1100-1109
4. UK Prospective Diabetes Study Group. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care. 21 (1998) 87-92
5. Bell D.S., and Ovalle F. How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea?. Endocr Pract 6 (2000) 293-295
6. Schwartz S., Fonseca V., Berner B., et al. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 29 (2006) 759-764
7. Hou S.Y., Cowles V.E., and Berner B. Gastric retentive dosage forms: A review. Crit Rev Ther Drug Carrier Syst. 20 (2003) 459-497
8. Gusler G., Gorsline J., Levy G., et al. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J Clin Pharmacol. 41 (2001) 655-661
9. Marathe P.H., Wen Y., Norton J., et al. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol. 50 (2000) 325-332
10. Foster R.H., and Keam S.J. Metformin extended release. Am J Drug Deliv. 4 (2006) 177-186
11. Scheen A.J. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30 (1996) 359-371
12. Cramer J. A systematic review of adherence with medications for diabetes. Diabetes Care. 27 (2006) 1218-1224
13. Available at:. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(Rl). 10 June 1996. Accessed. http://www.ich.org/LOB/media/MEDIA482.pdf May 8, 2007
14. Available at:. World Medical Association Declaration of Helsinki. Recommendations Guiding Medical Doctors in Biomedi cal Research Involving Human Subjects [WMA Web site]. Accessed (1989-May 8, 2007), WMA, Ferney-Voltaire, France. http://www.wma.net
15. The American Association of Clinical Endocrinologists Medical Guidelines for the management of diabetes mel litus. Endocrine Pract. 8 Suppl 1 (2002) 41-82
16. [published correction appears in Diabetes Care. 2006;29:1192]. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
17. Rosenstock J., Goldstein B.J., Vinik A.I., et al., RESULT Study Group. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): The Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab. 8 (2006) 49-57
18. [published correction appears in JAMA. 2000;284: 1384]. Fonseca V., Rosenstock J., Patwardhan R., and Salzman A. Effect of metformin and rosiglitazone combi nation therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA 283 (2000) 1695-1702
19. Resnick H.E., Foster G.L., Bardsley J., and Ratner R.E. Achievement of American Diabetes Association clinical prac tice recommendations among US adults with diabetes, 1999-2002: The National Health and Nutrition Examination Survey. Diabetes Care. 29 (2006) 531-537
20. Wulffele M.G., Kooy A., de Zeeuw D., et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: A systematic review. J Intern Med. 256 (2004) 1-14
21. Glumetza [package insert]. Menlo Park, Calif. Depomed Inc; 2006.